Abstract
We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P
| Original language | English |
|---|---|
| Pages (from-to) | 345-357 |
| Number of pages | 13 |
| Journal | International Immunopharmacology |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2005 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology
- Pharmacology
Cite this
Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice. / Edwan, Jehad H.; Talmadge, James E.; Agrawal, Devendra K.
In: International Immunopharmacology, Vol. 5, No. 2, 02.2005, p. 345-357.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice
AU - Edwan, Jehad H.
AU - Talmadge, James E.
AU - Agrawal, Devendra K.
PY - 2005/2
Y1 - 2005/2
N2 - We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P
AB - We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P
UR - http://www.scopus.com/inward/record.url?scp=12344298548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12344298548&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2004.10.002
DO - 10.1016/j.intimp.2004.10.002
M3 - Article
C2 - 15652764
AN - SCOPUS:12344298548
VL - 5
SP - 345
EP - 357
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
IS - 2
ER -